Latvia - latvisk - Zāļu valsts aģentūra

zentiva, k.s., czech republic - rivaroksabans - apvalkotā tablete - 2,5 mg

Latvia - latvisk - Zāļu valsts aģentūra

pharmaceutical works polpharma sa, poland - rosuvastatīns - apvalkotā tablete - 15 mg

Latvia - latvisk - Zāļu valsts aģentūra

pharmaceutical works polpharma sa, poland - rosuvastatīns - apvalkotā tablete - 30 mg

Latvia - latvisk - Zāļu valsts aģentūra

krka, d.d., novo mesto, slovenia - rivaroksabans - apvalkotā tablete - 2,5 mg

Latvia - latvisk - Zāļu valsts aģentūra

zentiva, k.s., czech republic - rivaroksabans - kapsula, cietā - 2,5 mg

Den europeiske union - latvisk - EMA (European Medicines Agency)

accord healthcare s.l.u. - rivaroxaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antitrombotiskie līdzekļi - venozās trombembolijas (vte) profilakse pieaugušiem pacientiem, kuriem tiek veikta gēnu vai ceļa locītavas locītavas operācija. Ārstēšana ar dziļo vēnu tromboze (dvt) un plaušu embolija (pe), un novērst atkārtotu dvt un pe pieaugušajiem. (see section 4. 4 for haemodynamically unstable pe patients. Ārstēšana ar dziļo vēnu tromboze (dvt) un plaušu embolija (pe), un novērst atkārtotu dvt un pe pieaugušajiem. (see section 4. 4 haemodynamically nestabila pe pacientiem). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. Ārstēšana ar dziļo vēnu tromboze (dvt) un plaušu embolija (pe), un novērst atkārtotu dvt un pe pieaugušajiem. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 un 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. Ārstēšana ar dziļo vēnu tromboze (dvt) un plaušu embolija (pe), un novērst atkārtotu dvt un pe pieaugušajiem. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Latvia - latvisk - Zāļu valsts aģentūra

auxilia pharma oÜ, estonia - rivaroksabans - apvalkotā tablete - 2,5 mg

Latvia - latvisk - Zāļu valsts aģentūra

sandoz d.d., slovenia - rivaroksabans - apvalkotā tablete - 2,5 mg

Latvia - latvisk - Zāļu valsts aģentūra

zentiva, k.s., czech republic - rosuvastatinum, ezetimibum - apvalkotā tablete - 10 mg/10 mg

Latvia - latvisk - Zāļu valsts aģentūra

zentiva, k.s., czech republic - rosuvastatinum, ezetimibum - apvalkotā tablete - 20 mg/10 mg